EP
VTYX

Essential Partners’s Ventyx Biosciences VTYX Stock Holding History

Essential Partners’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-288
Closed -$896 – 2930
2025
Q3 		$896 Sell
288
-1,174
-80% -$3.11K ﹤0.01% 2053
2025
Q2 		$3.13K Buy
+1,462
New +$2.36K ﹤0.01% 1188

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Essential Partners's VTYX Position: Q4 2025 in Review

Essential Partners sold out of Ventyx Biosciences (VTYX) in Q4 2025, closing a stake of 288 shares — an estimated $896 sold.

Essential Partners first reported a position in VTYX in Q2 2025 and held it in 2 quarters. The position peaked at $3.13K in Q2 2025. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Essential Partners reported no remaining Ventyx Biosciences position as of Q4 2025 after selling out during the quarter.
  • Essential Partners sold 288 Ventyx Biosciences shares in Q4 2025, an estimated $896.
  • Essential Partners first reported a position in Ventyx Biosciences in Q2 2025 and held it in 2 quarters.
  • Essential Partners's Ventyx Biosciences position peaked at $3.13K in Q2 2025.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Essential Partners's 13F filing for Q4 2025, filed 21 May 2026.